hVIVO #HVO – RSV human challenge trial contract signed with new client, Inhalon Biopharma February 3, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a contract with Inhalon Biopharma, Inc. (“Inhalon”), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections, to assess its inhaled IN-002 antiviral candidate (“IN-002”) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model. The Phase 2a randomised, double-blinded…

Continue reading